JP2010505473A - 交換可能なポンプヘッドを有する蠕動マイクロポンプ - Google Patents
交換可能なポンプヘッドを有する蠕動マイクロポンプ Download PDFInfo
- Publication number
- JP2010505473A JP2010505473A JP2009530776A JP2009530776A JP2010505473A JP 2010505473 A JP2010505473 A JP 2010505473A JP 2009530776 A JP2009530776 A JP 2009530776A JP 2009530776 A JP2009530776 A JP 2009530776A JP 2010505473 A JP2010505473 A JP 2010505473A
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- medical device
- pump head
- technical
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002572 peristaltic effect Effects 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 223
- 102000004877 Insulin Human genes 0.000 claims abstract description 115
- 108090001061 Insulin Proteins 0.000 claims abstract description 115
- 229940125396 insulin Drugs 0.000 claims abstract description 109
- 239000003814 drug Substances 0.000 claims abstract description 58
- 229940079593 drug Drugs 0.000 claims abstract description 53
- 241001465754 Metazoa Species 0.000 claims abstract description 24
- 238000002347 injection Methods 0.000 claims description 64
- 239000007924 injection Substances 0.000 claims description 64
- 230000007246 mechanism Effects 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 19
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 229920000669 heparin Polymers 0.000 claims description 11
- 229960002897 heparin Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 9
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 8
- 108010051696 Growth Hormone Proteins 0.000 claims description 8
- 102000018997 Growth Hormone Human genes 0.000 claims description 8
- 239000000122 growth hormone Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 3
- 108010092217 Long-Acting Insulin Proteins 0.000 claims description 3
- 229940100066 Long-acting insulin Drugs 0.000 claims description 3
- 108010026951 Short-Acting Insulin Proteins 0.000 claims description 3
- 229940123958 Short-acting insulin Drugs 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 239000000813 peptide hormone Substances 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- 229940127560 insulin pen Drugs 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000013461 design Methods 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 102100040918 Pro-glucagon Human genes 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000004026 insulin derivative Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010000521 Human Growth Hormone Proteins 0.000 description 4
- 102000002265 Human Growth Hormone Human genes 0.000 description 4
- 108010057186 Insulin Glargine Proteins 0.000 description 4
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940060975 lantus Drugs 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 208000002230 Diabetic coma Diseases 0.000 description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- 102000016261 Long-Acting Insulin Human genes 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 229940112930 apidra Drugs 0.000 description 2
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108700039926 insulin glulisine Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100022977 Antithrombin-III Human genes 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010052097 Dawn phenomenon Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000005980 Gibberellic acid Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 101710186643 Insulin-2 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 201000006824 bubonic plague Diseases 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000005057 finger movement Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960001382 insulin argine Drugs 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940118179 lovenox Drugs 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
- F04B23/00—Pumping installations or systems
- F04B23/02—Pumping installations or systems having reservoirs
- F04B23/025—Pumping installations or systems having reservoirs the pump being located directly adjacent the reservoir
- F04B23/028—Pumping installations or systems having reservoirs the pump being located directly adjacent the reservoir the pump being mounted on top of the reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14212—Pumping with an aspiration and an expulsion action
- A61M5/14232—Roller pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
- F04B23/00—Pumping installations or systems
- F04B23/02—Pumping installations or systems having reservoirs
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
- F04B43/00—Machines, pumps, or pumping installations having flexible working members
- F04B43/12—Machines, pumps, or pumping installations having flexible working members having peristaltic action
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
- F04B43/00—Machines, pumps, or pumping installations having flexible working members
- F04B43/12—Machines, pumps, or pumping installations having flexible working members having peristaltic action
- F04B43/1253—Machines, pumps, or pumping installations having flexible working members having peristaltic action by using two or more rollers as squeezing elements, the rollers moving on an arc of a circle during squeezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M2005/14268—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body with a reusable and a disposable component
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8293—Solar
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
- F04B2201/00—Pump parameters
- F04B2201/02—Piston parameters
- F04B2201/0207—Number of pumping strokes in unit time
Abstract
Description
a)モータ;
b)リザーバ;
c)a)のモータによって駆動され、そしてそれによって液体がリザーバから搬出されるポンプヘッド;
d)制御用電子機器;
を含み、ここでc)のポンプヘッドが、a)のモータ及び/又はb)のリザーバ及び/又はd)の制御用電子機器に、着脱可能で再接続可能なインターフェースを備える装置に関する。
a)モータを備え;
b)リザーバを備え;
c)ポンプヘッドを備え;
d)a)からc)に記載された個々の構成要素を組み立てて機能的ユニットを得る;
製造に関する。
a)ハウジング;及び/又は
b)医療器具によって送達すべき薬剤の量を予め設定するための調整機構;及び/又は
c)表示装置;及び/又は
d)注射を開始しそして実行するための放出機構;
を含み、これは1つ又はそれ以上の上記の実施態様における少なくとも1つの本発明の装置を更に含む、医療器具に関する。
LP−1又はヘパリンを注射するためにある。インスリンは、動物又はヒト起源の、又は従来法若しくは遺伝子操作によって生産されているものの長時間作用型、短時間作用型、混合型インスリン若しくは通常作用型インスリンであってよく、そして溶液又は懸濁液の形態であってよい。
a)ハウジングを備え;
b)医療器具によって送達すべき薬剤の量を予め設定するために調整機構を備え;
c)表示装置を備え;
d)放出機構を備え;
e)場合により電子的構成要素を備え;
f)上記の1つ又はそれ以上の実施態様における少なくとも1つの本発明による装置を備え;
g)a)からf)に記載された個々の構成要素を組み立てて、機能的ユニットを得る;製造に関する。
a) 空腹時血糖:7.0mmol/L又は126mg/dL;
b) 75mgのブドウ糖投与後2時間の血糖(経口ブドウ糖負荷試験):11.1mmol/L又は200 mg/dL;
c) 重篤な口渇 (多飲症)、頻尿(多尿症)又は体重減少と関連した血糖:11.1mmol/L又は200mg/dL;
の少なくとも1つに記載された値を超えた場合に使われる用語である。
ポンプヘッドは、ハウジング中に収納されるポンプ室(チュービングポンプ)及び流量センサ(インペラ式流量計)から成る。ハウジングは、容易に分離可能で再び閉じることができるインターフェースを有する(図5)。
2 本体(下側)
3 交換可能なポンプヘッド
4 本体(上側)
5 カートリッジ・コンパートメントのカバー
6 カートリッジ・コンパートメント
7 カートリッジ
8 カートリッジ表示ウィンドウ
9 交換可能なポンプヘッドを受けるための本体コネクター
10 本体と交換可能なポンプヘッドとの間の保持具
11 モータ
12 モータカップリング
13 断続器
14 LCDを備えた電子部品(裏側)
15 LCD表示装置
16 カメラバッテリー
17 PCに対するインターフェース
18 ON/OFFスイッチ
19 スタートボタン
20 投与ボタン
21 交換可能なポンプヘッドと本体との接触領域
22 ポンプへのカップリング
23 カートリッジに対するインターフェース
24 針に対するインターフェース
25 針
26 本体と交換可能なポンプヘッドの間の保持具
27 交換可能なポンプヘッドの基本部分(外側)
28 交換可能なポンプヘッドの基本部分(内側(outerside))
29 交換可能なポンプヘッドのカバー部分
30 ロータ
31 ロール
32 チュービング
33 羽のエッジ部
34 流量センサ
35 流体部分
Claims (27)
- 薬剤を含む液体を動かすための装置であって、その技術的装置が少なくとも
a)モータ;
b)リザーバ;
c)a)のモータによって駆動され、そしてそれによって液体がリザーバから搬出されるポンプヘッド;
d)制御用電子機器;
を含み、ここでc)のポンプヘッドが、a)のモータ及び/又はb)のリザーバ及び/又はd)の制御用電子機器に着脱可能で機能的に再接続可能なインターフェースを備える装置。 - ポンプヘッドが別のポンプヘッドと容易に交換され得る、請求項1に記載の技術的装置。
- ポンプヘッドが流量センサ及び/又は流量センサの構成部品を含む、請求項1又は2に記載の技術的装置。
- ポンプヘッドが針を支持する、請求項1〜3のいずれか1項に記載の技術的装置。
- モータがマイクロモータから成る、請求項1〜4のいずれか1項に記載の技術的装置。
- リザーバが、薬剤を受けるための商業的に入手可能なカートリッジである、請求項1〜5のいずれか1項に記載の技術的装置。
- リザーバがインスリンを含む、請求項1〜6のいずれか1項に記載の技術的装置。
- ヒト又は動物の体内に物質を注射するための、請求項1〜7のいずれか1項に記載の装置の使用。
- 請求項1〜8のいずれか1項に記載の装置の製造であって、
a)モータを備え;
b)リザーバを備え;
c)ポンプヘッドを備え;
d)a)からc)に記載された個々の構成要素を組み立てて、機能的ユニットを得る;製造。 - 薬剤をヒト又は動物の体内に注射するための医療器具であって、とりわけ
a)ハウジング;
b)医療器具によって送達すべき医薬品の量を予め設定するための調整機構;
c)表示装置;
d)注射を開始し、そして実行するための放出機構の形態の技術的ユニット;
を含み、請求項1〜7のいずれか1項に記載の少なくとも1つの装置を更に含む医療器具。 - 表示装置がLCD表示装置から成る、請求項10に記載の医療器具。
- データ及び/又は信号を記憶及び/又は処理するための少なくとも1つの手段、及びデータ及び/又は信号を記憶及び/又は処理するために構成される外部の技術的ユニットへ及び/又はその技術的ユニットから、データ及び/又は信号データを伝送するための少なくとも1つのインターフェースを含む、請求項10又は11に記載の医療器具。
- 外部の技術的ユニットが、データ及び/又は信号を記憶及び/又は処理するためのプログラムが搭載されているPCから成る、請求項12に記載の医療器具。
- 注射対象の物質がインスリンから成る、請求項10〜13のいずれか1項に記載の医療器具。
- インスリンが長時間作用型及び/又は短時間作用型インスリンである、請求項14に記載の医療器具。
- 注射対象の物質がGLP−1から成る、請求項10〜13のいずれか1項に記載の医療器具。
- 注射対象の物質がヘパリンから成る、請求項10〜13のいずれか1項に記載の医療器具。
- 請求項9〜16のいずれか1項に記載の、薬剤をヒト又は動物の体内に注射するための医療器具の製造であって、
a)ハウジングを備え;
b)医療器具によって送達されるべき薬剤の量を予め設定するために調整機構を備え;
c)表示装置を備え;
d)放出機構を備え;
e)場合により電子的構成要素を備え;
f)請求項1〜7のいずれか1項に記載の技術的装置を備え;
g)a)からf)に記載された個々の構成要素を組み立てて、機能的ユニットを得る;製造。 - 請求項10〜13のいずれか1項に記載の医療器具の使用であって、薬理活性が消化管で損なわれるか消失する物質を用いた、疾患及び/又は体の機能障害の予防及び/又は治療のための使用。
- 糖尿病の治療のための、請求項10〜13のいずれか1項に記載の医療器具の使用。
- インスリンの投与のための、請求項10〜13のいずれか1項に記載の医療器具の使用。
- GLP−1の投与のための、請求項10〜13のいずれか1項に記載の医療器具の使用。
- ペプチド・ホルモンを投与するための、請求項10〜13のいずれか1項に記載の医療器具の使用。
- 成長ホルモンを投与するための、請求項10〜13のいずれか1項に記載の医療器具の使用。
- ヘパリンを投与するための、請求項10〜13のいずれか1項に記載の医療器具の使用。
- ロベノックスを投与するための、請求項10〜13のいずれか1項に記載の医療器具の使用。
- ワクチンを投与するための、請求項10〜13のいずれか1項に記載の医療器具の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006047613.1 | 2006-10-07 | ||
DE102006047613A DE102006047613A1 (de) | 2006-10-07 | 2006-10-07 | Peristaltische Mikropumpe mit wechselbarem Pumpenkopf |
PCT/EP2007/008361 WO2008040477A1 (de) | 2006-10-07 | 2007-09-26 | Peristaltische mikropumpe mit wechselbarem pumpenkopf |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010505473A true JP2010505473A (ja) | 2010-02-25 |
JP5401317B2 JP5401317B2 (ja) | 2014-01-29 |
Family
ID=38925490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009530776A Active JP5401317B2 (ja) | 2006-10-07 | 2007-09-26 | 交換可能なポンプヘッドを有する蠕動マイクロポンプ |
Country Status (20)
Country | Link |
---|---|
US (1) | US8496621B2 (ja) |
EP (1) | EP2077874B1 (ja) |
JP (1) | JP5401317B2 (ja) |
KR (1) | KR101477479B1 (ja) |
CN (1) | CN101522237B (ja) |
AR (1) | AR063136A1 (ja) |
AT (1) | ATE524208T1 (ja) |
AU (1) | AU2007304460A1 (ja) |
BR (1) | BRPI0719231A2 (ja) |
CA (1) | CA2665272C (ja) |
DE (1) | DE102006047613A1 (ja) |
DK (1) | DK2077874T3 (ja) |
ES (1) | ES2373590T3 (ja) |
HK (1) | HK1135624A1 (ja) |
IL (1) | IL197973A (ja) |
MX (1) | MX2009003429A (ja) |
MY (1) | MY149557A (ja) |
NO (1) | NO20091801L (ja) |
TW (1) | TWI458508B (ja) |
WO (1) | WO2008040477A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012532716A (ja) * | 2009-07-14 | 2012-12-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 注射装置 |
JP7143258B2 (ja) | 2013-10-24 | 2022-09-28 | トラスティーズ オブ ボストン ユニバーシティ | 多数の薬剤の誤送出を防止するための注入システム |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201103594A (en) * | 2009-06-02 | 2011-02-01 | Sanofi Aventis Deutschland | Medicated module with premix medicament |
TR201902455T4 (tr) * | 2009-07-14 | 2019-03-21 | Sanofi Aventis Deutschland | Bir peristaltik pompa için pompa haznesi. |
JP5727473B2 (ja) * | 2009-07-14 | 2015-06-03 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 注射装置 |
EP2461804A4 (en) * | 2009-08-04 | 2013-10-02 | Haren Treasurer | IMPROVED USE WITH THYROID HORMONE |
KR101939267B1 (ko) | 2010-07-21 | 2019-01-16 | 삼성전자주식회사 | 주사기의 주사량 측정 장치 및 방법 |
ITVR20120034A1 (it) * | 2012-03-02 | 2013-09-03 | Tecres Spa | Dispositivo infusore universale per liquidi medicinali e simili, e metodo per il controllo dell'erogazione di liquido medicinale e simili. |
DE202012009627U1 (de) * | 2012-10-09 | 2013-10-11 | Hirschmann Laborgeräte GmbH & Co. KG | Schlauchpumpe |
CN106029122A (zh) * | 2013-12-20 | 2016-10-12 | 赛诺菲-安万特德国有限公司 | 具有一次性药筒和一次性注射器的药物输送装置 |
US20160144137A1 (en) * | 2014-11-24 | 2016-05-26 | Paul S. Shapiro | Retractable insulin infusion system |
EP3085404A1 (en) * | 2015-04-21 | 2016-10-26 | Sanofi-Aventis Deutschland GmbH | Dosing mechanism and drug delivery device |
DE102015005286A1 (de) * | 2015-04-25 | 2016-10-27 | Thomas Magnete Gmbh | Vorrichtung zum Fördern und Dosieren mit einer Signaleinrichtung |
JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
USD809134S1 (en) * | 2016-03-10 | 2018-01-30 | Bigfoot Biomedical, Inc. | Infusion pump assembly |
IL296753B1 (en) | 2016-06-16 | 2024-01-01 | Smiths Medical Asd Inc | Assemblies and methods for infusion pump system delivery kits |
USD806233S1 (en) | 2016-09-09 | 2017-12-26 | Liebel-Flarsheim Company Llc | Powerhead for a power injection system |
EP3519011A4 (en) | 2016-09-27 | 2020-05-20 | Bigfoot Biomedical, Inc. | SYSTEMS, DEVICES AND METHODS FOR MEDICATION INJECTION AND DISEASE MANAGEMENT |
AU2017376111B2 (en) | 2016-12-12 | 2023-02-02 | Bigfoot Biomedical, Inc. | Alarms and alerts for medication delivery devices and related systems and methods |
USD836769S1 (en) | 2016-12-12 | 2018-12-25 | Bigfoot Biomedical, Inc. | Insulin delivery controller |
US9636460B1 (en) | 2016-12-28 | 2017-05-02 | Creare Llc | Pneumatic autoinjector with automated mixing |
USD839294S1 (en) | 2017-06-16 | 2019-01-29 | Bigfoot Biomedical, Inc. | Display screen with graphical user interface for closed-loop medication delivery |
EP3651647A1 (en) | 2017-07-13 | 2020-05-20 | Bigfoot Biomedical, Inc. | Multi-scale display of blood glucose information |
WO2019018658A2 (en) | 2017-07-19 | 2019-01-24 | Smiths Medical Asd, Inc. | PENCIL ARRANGEMENTS FOR INFUSION PUMPS |
DE202018005253U1 (de) | 2018-11-12 | 2018-12-03 | MeDiPa GmbH | Auswechselbare volumetrische Dosiereinheit |
US11602622B2 (en) * | 2019-09-24 | 2023-03-14 | The Charles Stark Draper Laboratory, Inc. | Wearable micropump for therapeutic drug delivery |
TWI715254B (zh) * | 2019-10-18 | 2021-01-01 | 美商康華全球生技股份有限公司 | 智能藥物注射裝置 |
KR102333659B1 (ko) * | 2019-10-30 | 2021-12-02 | 주식회사 필로시스 | 약물 주입 장치 및 방법 |
DE102019217315A1 (de) * | 2019-11-08 | 2021-05-12 | B. Braun Melsungen Aktiengesellschaft | Infusionssystem, Rotormodul zur Verwendung in einem solchen Infusionssystem und Verfahren zur Ermittlung einer Durchflussrate einer Infusionsflüssigkeit in einem solchen Infusionssystem |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09504974A (ja) * | 1993-11-18 | 1997-05-20 | イーラン・メディカル・テクノロジーズ・リミテッド | 皮膚内薬剤給送装置 |
JP2002126092A (ja) * | 2000-07-31 | 2002-05-08 | Becton Dickinson & Co | 装身可能な自蔵式薬物輸液装置 |
US20040191086A1 (en) * | 2003-03-31 | 2004-09-30 | Paukovits Edward J. | Disposable fluid delivery system |
JP2004532670A (ja) * | 2001-02-22 | 2004-10-28 | インシュレット コーポレイション | モジュール式の輸液装置及び方法 |
WO2004110526A1 (de) * | 2003-06-17 | 2004-12-23 | Disetronic Licensing Ag | Modulare infusionspumpe |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241704B1 (en) * | 1901-11-22 | 2001-06-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US4187057A (en) * | 1978-01-11 | 1980-02-05 | Stewart-Naumann Laboratories, Inc. | Peristaltic infusion pump and disposable cassette for use therewith |
US5755683A (en) * | 1995-06-07 | 1998-05-26 | Deka Products Limited Partnership | Stopcock valve |
IL107038A (en) * | 1992-10-05 | 1997-04-15 | Senetek Plc | Medicament injectors and methods for injection using same |
US5558639A (en) * | 1993-06-10 | 1996-09-24 | Gangemi; Ronald J. | Ambulatory patient infusion apparatus |
US5462525A (en) * | 1994-06-14 | 1995-10-31 | Minimed, Inc., A Delaware Corporation | Flow sensor for an infusion pump |
US5582593A (en) * | 1994-07-21 | 1996-12-10 | Hultman; Barry W. | Ambulatory medication delivery system |
WO1997002059A1 (en) | 1995-07-06 | 1997-01-23 | Disetronic Licensing Ag | Disposable cassette for connection to a liquid drug infusion pump |
DE19745999A1 (de) | 1997-10-20 | 1999-04-22 | Horst Jungkeit | Modulare Miniaturschlauchpumpe zur Förderung von flüssigen Medien |
DE19916876A1 (de) | 1999-04-14 | 2000-11-02 | Clemens Micheler | Medizinische Dosierpumpe |
IL156245A0 (en) * | 2000-12-22 | 2004-01-04 | Dca Design Int Ltd | Drive mechanism for an injection device |
US7320676B2 (en) * | 2003-10-02 | 2008-01-22 | Medtronic, Inc. | Pressure sensing in implantable medical devices |
EP1535637A1 (en) | 2003-11-28 | 2005-06-01 | Woo Young Medical Co., Ltd. | Automatic dose infusion apparatus |
CN100560147C (zh) * | 2004-01-17 | 2009-11-18 | 珠海福尼亚医疗设备有限公司 | 一种胰岛素泵及其操作系统和流程 |
DE102006047538A1 (de) | 2006-10-07 | 2008-04-10 | Sanofi-Aventis Deutschland Gmbh | Medikamentendosiersystem mittels Mikropumpe |
-
2006
- 2006-10-07 DE DE102006047613A patent/DE102006047613A1/de not_active Ceased
-
2007
- 2007-09-26 MX MX2009003429A patent/MX2009003429A/es active IP Right Grant
- 2007-09-26 EP EP07818445A patent/EP2077874B1/de not_active Revoked
- 2007-09-26 ES ES07818445T patent/ES2373590T3/es active Active
- 2007-09-26 BR BRPI0719231-2A patent/BRPI0719231A2/pt not_active IP Right Cessation
- 2007-09-26 DK DK07818445.4T patent/DK2077874T3/da active
- 2007-09-26 JP JP2009530776A patent/JP5401317B2/ja active Active
- 2007-09-26 WO PCT/EP2007/008361 patent/WO2008040477A1/de active Application Filing
- 2007-09-26 KR KR20097006998A patent/KR101477479B1/ko not_active IP Right Cessation
- 2007-09-26 CN CN2007800374864A patent/CN101522237B/zh active Active
- 2007-09-26 CA CA2665272A patent/CA2665272C/en not_active Expired - Fee Related
- 2007-09-26 AU AU2007304460A patent/AU2007304460A1/en not_active Abandoned
- 2007-09-26 AT AT07818445T patent/ATE524208T1/de active
- 2007-09-26 MY MYPI20091241A patent/MY149557A/en unknown
- 2007-10-04 TW TW096137188A patent/TWI458508B/zh not_active IP Right Cessation
- 2007-10-04 AR ARP070104407A patent/AR063136A1/es not_active Application Discontinuation
-
2009
- 2009-03-31 US US12/415,232 patent/US8496621B2/en active Active
- 2009-04-05 IL IL197973A patent/IL197973A/en not_active IP Right Cessation
- 2009-05-06 NO NO20091801A patent/NO20091801L/no not_active Application Discontinuation
-
2010
- 2010-03-02 HK HK10102244.8A patent/HK1135624A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09504974A (ja) * | 1993-11-18 | 1997-05-20 | イーラン・メディカル・テクノロジーズ・リミテッド | 皮膚内薬剤給送装置 |
JP2002126092A (ja) * | 2000-07-31 | 2002-05-08 | Becton Dickinson & Co | 装身可能な自蔵式薬物輸液装置 |
JP2004532670A (ja) * | 2001-02-22 | 2004-10-28 | インシュレット コーポレイション | モジュール式の輸液装置及び方法 |
US20040191086A1 (en) * | 2003-03-31 | 2004-09-30 | Paukovits Edward J. | Disposable fluid delivery system |
WO2004110526A1 (de) * | 2003-06-17 | 2004-12-23 | Disetronic Licensing Ag | Modulare infusionspumpe |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012532716A (ja) * | 2009-07-14 | 2012-12-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 注射装置 |
JP7143258B2 (ja) | 2013-10-24 | 2022-09-28 | トラスティーズ オブ ボストン ユニバーシティ | 多数の薬剤の誤送出を防止するための注入システム |
Also Published As
Publication number | Publication date |
---|---|
MY149557A (en) | 2013-09-13 |
HK1135624A1 (en) | 2010-06-11 |
DE102006047613A1 (de) | 2008-04-10 |
US20090292247A1 (en) | 2009-11-26 |
ATE524208T1 (de) | 2011-09-15 |
BRPI0719231A2 (pt) | 2014-04-29 |
NO20091801L (no) | 2009-06-30 |
US8496621B2 (en) | 2013-07-30 |
WO2008040477A1 (de) | 2008-04-10 |
CN101522237B (zh) | 2013-11-06 |
TW200900100A (en) | 2009-01-01 |
MX2009003429A (es) | 2009-06-12 |
DK2077874T3 (da) | 2012-01-16 |
EP2077874B1 (de) | 2011-09-14 |
IL197973A0 (en) | 2009-12-24 |
CN101522237A (zh) | 2009-09-02 |
AU2007304460A1 (en) | 2008-04-10 |
EP2077874A1 (de) | 2009-07-15 |
CA2665272A1 (en) | 2008-04-10 |
KR20090061032A (ko) | 2009-06-15 |
CA2665272C (en) | 2015-06-16 |
KR101477479B1 (ko) | 2015-01-06 |
TWI458508B (zh) | 2014-11-01 |
ES2373590T3 (es) | 2012-02-06 |
AR063136A1 (es) | 2008-12-30 |
IL197973A (en) | 2014-11-30 |
JP5401317B2 (ja) | 2014-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5401317B2 (ja) | 交換可能なポンプヘッドを有する蠕動マイクロポンプ | |
JP5118705B2 (ja) | ガラス製アンプルのストッパ位置の光学的決定方法 | |
CA2665274C (en) | Micropump-operated drug dosing system | |
AU2014201296B2 (en) | Peristaltic micropump having an exchangeable pump head | |
AU2016201150A1 (en) | Micropump-operated drug dosing system | |
AU2014201299A1 (en) | Micropump-operated drug dosing system | |
DE102006047537B4 (de) | Verfahren und Vorrichtung zur Bestimmung der Position eines Stopfens einer Ampulle für ein Arzneimittel in einem medizinischen Gerät sowie deren Verwendung, ein entsprechendes medizinisches Gerät sowie Herstellung eines medizinischen Geräts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100908 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120710 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130507 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130514 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131001 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131028 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5401317 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |